Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 3/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 14/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.45 |
| ▸ | SCN2B | O60939 | 2/20 | 0.45 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16361274 | 0.82 | SCN9A (0.49) | SCN9ASCN5ASCN2BSCN1BSCN1A | |
| SCHEMBL20118985 | 0.81 | HDAC8 (0.58) | KAT6ASCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL13209252 | 0.81 | KAT6A (0.58) | KAT6ASCN9ATP53BP1BRAFPTGER3 | |
| SCHEMBL20173762 | 0.78 | CA2 (0.56) | BRAF | |
| SCHEMBL30436806 | 0.78 | SCN2B (0.58) | KAT6ASCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL20178637 | 0.78 | SMYD3 (0.55) | KAT6ASCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL20173765 | 0.77 | ACHE (0.45) | — | |
| SCHEMBL20173760 | 0.77 | KAT6A (0.54) | KAT6ASCN9ATP53BP1PTGER3 | |
| SCHEMBL3808268 | 0.77 | HDAC3 (0.50) | KAT6ASCN9ASCN5A | |
| SCHEMBL14367222 | 0.77 | HDAC6 (0.59) | KAT6ATP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | KAT6A 2864/4885SCN9A 2939/4885TP53BP1 4448/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | KAT6A 2864/4885SCN9A 2939/4885TP53BP1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.